Geninus

Geninus P/CF

The P/CF (Price-to-Cash-Flow Ratio) of Geninus (389030.KQ) as of Nov 2, 2026 is -14.58. In the previous year, P/CF (Price-to-Cash-Flow Ratio) was -9.67 — a change of 50.74% (lower).

P/CF

-14.58

YoY

50.74%

Last updated:

P/CF (Price-to-Cash-Flow Ratio) of Geninus is 2025 -14.58 . P/CF (Price-to-Cash-Flow Ratio) of Geninus was 2024 -9.67 . It decreases by 50.74% lower compared to the previous year.

The Geninus P/CF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/CF
Date
P/CF
Jan 1, 2018
1,676.33 KRW
Jan 1, 2019
-43.95 KRW
Jan 1, 2020
55.99 KRW
Jan 1, 2021
-11.11 KRW
Jan 1, 2022
-8.65 KRW
Jan 1, 2023
-12.70 KRW
Jan 1, 2024
-9.67 KRW
Jan 1, 2025
-14.58 KRW
The Geninus P/CF history
YEARP/CFYoY
-14.58+50.74%
-9.67-23.86%
-12.70+46.92%
-8.65-22.19%
-11.11-119.85%
55.99-227.40%
-43.95-102.62%
1,676.33—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Geninus Stock analysis

What does Geninus do? Geninus Inc. generates revenue through the provision of single cell analysis services and genetic testing for disease prediction to the public. The company develops and manufactures genome analysis solutions, including cancer genome analysis based on tissue biopsy, and offers personal genetic testing services. Additionally, Geninus Inc. engages in software development and a rental business as part of its product portfolio. The primary customers are individuals seeking genetic insights for health management and healthcare providers requiring advanced genomic analysis tools. The company's products include NGS-based genome analysis technology, cancer genome analysis solutions, and personal genetic testing services. These offerings target healthcare institutions, medical professionals, and consumers interested in personalized health assessments. Geninus Inc. also develops software for genomic data processing, which supports its service delivery and rental business model. Revenue streams are derived from direct sales of genome analysis solutions, service fees for single cell and cancer genome analysis, and subscriptions for software and rental services. The firm's focus on NGS technology positions it within the biotechnology sector, serving both clinical and consumer markets with a range of genomic services and products. Geninus is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Geninus stock

P/CF (Price-to-Cash-Flow Ratio) of Geninus is -14.58 in 2025.

P/CF (Price-to-Cash-Flow Ratio) of Geninus changed from -9.67 to -14.58, representing a 50.74% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/CF (Price-to-Cash-Flow Ratio) Geninus since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Cash-Flow ratio measures the stock price relative to operating cash flow per share. Unlike P/E, it is harder to manipulate as cash flow is less subject to accounting adjustments.

P/CF = Stock Price / Operating Cash Flow per Share

To evaluate P/CF (Price-to-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/CF (Price-to-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/CF (Price-to-Cash-Flow Ratio)'s Geninus with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — Geninus

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Geninus